S Pol

Summary

Country: France

Publications

  1. ncbi request reprint Rapid progression of antiviral treatments of chronic hepatitis C virus infection
    S Pol
    Universite Paris Descartes, APHP, Unité d Hépatologie, Hopital Cochin, INSERM U 1016 Institut Cochin, Paris, France
    Minerva Gastroenterol Dietol 59:161-72. 2013
  2. doi request reprint Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure
    Stanislas Pol
    Universite Paris Descartes, INSERM Unité 1016, and Assistance Publique Hopitaux de Paris, Cochin Hospital, Paris, France
    J Hepatol 58:883-9. 2013
  3. doi request reprint Management of HBV in immunocompromised patients
    Stanislas Pol
    Inserm U 1016, Unité d Hépatologie, APHP Hôpital Cochin, Universite Paris Descartes, Paris, France
    Liver Int 33:182-7. 2013
  4. doi request reprint Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial
    Stanislas Pol
    Hopital Cochin, Paris, France
    Lancet Infect Dis 12:671-7. 2012
  5. pmc Hepatitis C virus-specific cellular immune responses in individuals with no evidence of infection
    Yves Riviere
    Laboratoire d Immunopathologie Virale, Institut Pasteur and CNRS URA 3015, 25 rue du Dr Roux, 75015 Paris, France
    Virol J 9:76. 2012
  6. pmc First-line treatment of chronic hepatitis B with entecavir or tenofovir in 'real-life' settings: from clinical trials to clinical practice
    S Pol
    Unité d Hépatologie, Hopital Cochin, Universite Paris Descartes, APHP, Inserm U 1016, Paris, France
    J Viral Hepat 19:377-86. 2012
  7. doi request reprint Hepatitis C: epidemiology, diagnosis, natural history and therapy
    Stanislas Pol
    Universite Paris Descartes, APHP, Hopital Cochin, Unité d Hépatologie, Institut Cochin, Paris, France
    Contrib Nephrol 176:1-9. 2012
  8. doi request reprint [Individualized treatment of hepatitis C virus infection]
    Stanislas Pol
    Universite Paris Descartes, AP HP, Hopital Cochin, Unité d Hépatologie, Inserm U 1016, 75014 Paris, France
    Presse Med 41:146-52. 2012
  9. pmc Hepatic profile analyses of tipranavir in Phase II and III clinical trials
    Jaromir Mikl
    SUNY at Albany, School of Public Health, Rensselaer NY, USA
    BMC Infect Dis 9:203. 2009
  10. doi request reprint Management of chronic hepatitis C virus infection in HIV-infected patients
    Stanislas Pol
    Liver Unit, Universite Paris Descartes, Hopital Cochin, Paris, France
    Clin Infect Dis 47:94-101. 2008

Detail Information

Publications125 found, 100 shown here

  1. ncbi request reprint Rapid progression of antiviral treatments of chronic hepatitis C virus infection
    S Pol
    Universite Paris Descartes, APHP, Unité d Hépatologie, Hopital Cochin, INSERM U 1016 Institut Cochin, Paris, France
    Minerva Gastroenterol Dietol 59:161-72. 2013
    ....
  2. doi request reprint Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure
    Stanislas Pol
    Universite Paris Descartes, INSERM Unité 1016, and Assistance Publique Hopitaux de Paris, Cochin Hospital, Paris, France
    J Hepatol 58:883-9. 2013
    ..This subanalysis of the REALIZE study evaluated the impact of IL28B polymorphisms on sustained virologic response (SVR) in telaprevir-treated, HCV genotype 1-infected patients with prior PegIFN/RBV treatment failure...
  3. doi request reprint Management of HBV in immunocompromised patients
    Stanislas Pol
    Inserm U 1016, Unité d Hépatologie, APHP Hôpital Cochin, Universite Paris Descartes, Paris, France
    Liver Int 33:182-7. 2013
    ....
  4. doi request reprint Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial
    Stanislas Pol
    Hopital Cochin, Paris, France
    Lancet Infect Dis 12:671-7. 2012
    ..Once-daily daclatasvir, a potent NS5A replication complex inhibitor, was generally well tolerated in phase 1 studies. We assessed daclatasvir in combination with pegylated interferon (peginterferon) and ribavirin for chronic HCV...
  5. pmc Hepatitis C virus-specific cellular immune responses in individuals with no evidence of infection
    Yves Riviere
    Laboratoire d Immunopathologie Virale, Institut Pasteur and CNRS URA 3015, 25 rue du Dr Roux, 75015 Paris, France
    Virol J 9:76. 2012
    ..This result would be consistent with unapparent primary HCV infections that either cleared spontaneously or remained undetected by conventional serological assays...
  6. pmc First-line treatment of chronic hepatitis B with entecavir or tenofovir in 'real-life' settings: from clinical trials to clinical practice
    S Pol
    Unité d Hépatologie, Hopital Cochin, Universite Paris Descartes, APHP, Inserm U 1016, Paris, France
    J Viral Hepat 19:377-86. 2012
    ..Low incidences of drug resistance and favourable tolerabilities were reported for both drugs, thus confirming the results from registration trials...
  7. doi request reprint Hepatitis C: epidemiology, diagnosis, natural history and therapy
    Stanislas Pol
    Universite Paris Descartes, APHP, Hopital Cochin, Unité d Hépatologie, Institut Cochin, Paris, France
    Contrib Nephrol 176:1-9. 2012
    ..The next step appears to be the combination of these oral drugs allowing a better safety and efficacy of the treatment...
  8. doi request reprint [Individualized treatment of hepatitis C virus infection]
    Stanislas Pol
    Universite Paris Descartes, AP HP, Hopital Cochin, Unité d Hépatologie, Inserm U 1016, 75014 Paris, France
    Presse Med 41:146-52. 2012
    ....
  9. pmc Hepatic profile analyses of tipranavir in Phase II and III clinical trials
    Jaromir Mikl
    SUNY at Albany, School of Public Health, Rensselaer NY, USA
    BMC Infect Dis 9:203. 2009
    ....
  10. doi request reprint Management of chronic hepatitis C virus infection in HIV-infected patients
    Stanislas Pol
    Liver Unit, Universite Paris Descartes, Hopital Cochin, Paris, France
    Clin Infect Dis 47:94-101. 2008
    ..Effective management strategies that encompass patient and viral factors are necessary to improve the long-term outlook for coinfected patients...
  11. ncbi request reprint [Treatment of hepatitis B. Current strategies]
    Stanislas Pol
    Service d Hepatologie, Hopital Cochin, Paris
    Gastroenterol Clin Biol 31:325-32. 2007
  12. doi request reprint [Chronic hepatitis B: unusual situations: dialysis, renal transplantation and pre-emptive therapy in immune compromised patients]
    S Pol
    Unité d Hépatologie, Hopital Cochin, 27, rue du Faubourg Saint Jacques, 75014 Paris, France
    Gastroenterol Clin Biol 32:S34-41. 2008
    ..These risks evidence that any HBs Ag carrier exposed to immune suppression has to be diagnosed, evaluated for viral replication and underlying liver disease and has to be treated by a so-called pre-emptive treatment based on analogues...
  13. doi request reprint [Treatment of chronic hepatitis B: adherence and safety]
    S Pol
    Unité d Hépatologie, Inserm U 567 et Université Paris V René Descartes, Hopital Cochin, Paris, France
    Gastroenterol Clin Biol 34:S142-8. 2010
    ..More than the neuromuscular or metabolic side effects (lactic acidosis), the renal and bone-related adverse events have to be monitored, followed-up and anticipated by good clinical practices...
  14. doi request reprint Hepatitis B virus infection and pregnancy
    Stanislas Pol
    Inserm U 1016, Unité d Hépatologie, Universite Paris Descartes, AP HP, Hopital Cochin, 27 rue du Faubourg Saint Jacques, 75014 Paris, France
    Clin Res Hepatol Gastroenterol 35:618-22. 2011
    ....
  15. ncbi request reprint [Management of HCV-HIV patients]
    Stanislas Pol
    Unité d Hépatologie, Hopital Cochin, 27 rue du Faubourg Saint Jacques, 75014 Paris
    Gastroenterol Clin Biol 31:4S7-12. 2007
    ..The harmful impact of HIV underlines the need for improving:..
  16. ncbi request reprint Improving anti-HCV therapy
    Stanislas Pol
    Université Paris Descartes APHP, Hopital Cochin, Hépatologie INSERM U 567, Institut Cochin Paris, France
    Discov Med 6:187-90. 2006
    ..The combination of interferon and ribavirin is effective in many patients. However, the right treatment doses and duration, among other attributes, have a large impact on the treatment outcome...
  17. doi request reprint [ANRS HC 02 RIBAVIC: histo-pathological impact]
    S Pol
    Universite Paris Descartes, Unité d Hépatologie, Hopital Cochin, APHP, INSERM U 567, France
    Gastroenterol Clin Biol 33:S106-9. 2009
    ..These results emphasize the need of early therapeutic interventions to increase the rate of sustained virologic response and to decrease the rate of liver complications in the most severe patients...
  18. doi request reprint [ANRS HC 02 RIBAVIC: impact of steatosis in HIV-HCV co-infection]
    S Pol
    Universite Paris Descartes, Unité d Hépatologie, Hopital Cochin, APHP, INSERM U 567, France
    Gastroenterol Clin Biol 33:S110-2. 2009
    ..In these trials, steatosis worsened the fibrosis progression but did not impact on the rate of sustained virological response. Finally, steatosis significantly decreases in patients with sustained virological response...
  19. doi request reprint Persistently normal alanine aminotransferase levels in HIV/HCV-coinfected patients: the role of steatosis
    F Bani-Sadr
    Groupe Hospitalier Universitaire Est, INSERM U 707, Universite Pierre et Marie Curie, Paris, France
    HIV Med 10:417-21. 2009
    ..We analysed factors associated with persistently normal ALT levels, defined as at least three consecutive normal ALT values over a 6-month period, in a group of 381 HIV/HCV-coinfected patients...
  20. doi request reprint Severe weight loss in HIV / HCV-coinfected patients treated with interferon plus ribavirin: incidence and risk factors
    F Bani-Sadr
    Groupe Hospitalier Universitaire Est, Universite Paris 6, INSERM U707, Paris, France
    J Viral Hepat 15:255-60. 2008
    ..These findings show that severe weight loss is a frequent side effect of anti-HCV therapy in HIV / HCV-coinfected patients. The underlying mechanisms remain to be identified...
  21. doi request reprint Severe transaminitis after interferon-ribavirin therapy in HIV/HCV-coinfected patients: influence of a sustained HCV response
    F Bani-Sadr
    Groupe Hospitalier Universitaire Est, INSERM U 707, Universite Pierre et Marie Curie, UMR S 707, UPMC Paris 6, Paris, France
    J Viral Hepat 19:431-5. 2012
    ..Treatment of HCV infection should therefore be a priority in HIV-coinfected patients. Stavudine is associated with an increased risk of severe transaminitis...
  22. ncbi request reprint Combination of ribavirin and interferon-alfa surpasses high doses of interferon-alfa alone in patients with genotype-1b-related chronic hepatitis C
    S Pol
    Unité d hépatologie et Inserm U 370, Hopital Necker Enfants Malades, Paris, France
    Hepatology 31:1338-44. 2000
    ..In 1b-infected patients, the combination of high doses of interferon-alfa (6 MU) and ribavirin for 12 months appears to be the best therapy, with a high rate of sustained response...
  23. ncbi request reprint Hepatitis activity index is a key factor in determining the natural history of chronic hepatitis C
    H Fontaine
    , , Paris, France
    Hum Pathol 32:904-9. 2001
    ..Fibrosis progression is significantly associated with the necroinflammatory activity suggesting that this factor should be regarded as a major clue for deciding therapy...
  24. ncbi request reprint Risk factors for anaemia in human immunodeficiency virus/hepatitis C virus-coinfected patients treated with interferon plus ribavirin
    F Bani-Sadr
    Groupe Hospitalier Universitaire Est, Universite Paris, INSERM U707, Paris, France
    J Viral Hepat 14:639-44. 2007
    ..26-0.49, P < 0.0001) and in patients receiving protease inhibitor-based antiretroviral therapy (OR, 0.51 95% CI, 0.30-0.86, P = 0.0114). Zidovudine discontinuation could help to avoid anaemia associated with anti-HCV therapy...
  25. ncbi request reprint Sexually transmitted acute infection with a clustered genotype 4 hepatitis C virus in HIV-1-infected men and inefficacy of early antiviral therapy
    Jeanne Serpaggi
    Hepatology Unit, Necker Hospital, Paris, France
    AIDS 20:233-40. 2006
    ....
  26. doi request reprint New treatments for chronic hepatitis C virus infection
    M Corouge
    Unité d Hépatologie, Hopital Cochin, Universite Paris Descartes, AP HP, Inserm U 1016, 27, Institut Cochin, rue du Faubourg Saint Jacques, 75679 Paris cedex, France
    Med Mal Infect 41:579-87. 2011
    ..In the future, the main limitations of triple therapy will be safety (cutaneous rash or anemia which may be controlled), cost, compliance, viral resistance, and drug interactions that must be avoided by educating patients and physicians...
  27. ncbi request reprint Serum alpha-foetoprotein level predicts treatment outcome in chronic hepatitis C
    Sylvia Males
    Unité d Epidémiologie des Maladies Emergentes, Institut Pasteur, Paris, France
    Antivir Ther 12:797-803. 2007
    ..To analyse the association between serum alpha-foetoprotein (AFP) levels and sustained virological response (SVR) in treated patients...
  28. ncbi request reprint Improving anti-hepatitis C virus therapy
    Stanislas Pol
    Hopital Necker, APHP, Unité d Hépatologie, 149 rue de Sevres, 75015 Paris Cedex 15, France
    Expert Opin Biol Ther 6:923-33. 2006
    ....
  29. ncbi request reprint Risks factors of liver fibrosis in a cohort of intravenous drug users coinfected with HIV and HCV in the HAART era: the role of mixed steatosis
    Fanny Lanternier
    Service des Maladies Infectieuses et Tropicales, Hopital Cochin, 149 rue de Sevres, Paris
    Gastroenterol Clin Biol 31:822-7. 2007
    ..In this cohort of HIV/HCV coinfected intravenous drug user patients, METAVIR activity score, mixed steatosis and a low CD4 cell count were independent factors associated with severe liver fibrosis...
  30. ncbi request reprint Hepatic steatosis in HIV-HCV coinfected patients: analysis of risk factors
    Firouzé Bani-Sadr
    Groupe Hospitalier Universitaire Est, Universite Paris 6, INSERM V707, Paris, France
    AIDS 20:525-31. 2006
    ..To evaluate the prevalence and severity of steatosis and possible interactions between steatosis, host factors, viral factors, and treatment for HIV infection in HIV-hepatitis C virus (HCV) coinfected patients...
  31. doi request reprint The accuracy of the FIB-4 index for the diagnosis of mild fibrosis in chronic hepatitis B
    V Mallet
    Universite Paris Descartes, Paris, France
    Aliment Pharmacol Ther 29:409-15. 2009
    ..The Fib-4 index is a simple and inexpensive biomarker to delineate liver fibrosis in chronic hepatitis C...
  32. doi request reprint [HIV and hepatitis C virus coinfection]
    P Cacoub
    Service de Medecine Interne, AP HP, hôpital La Pitié Salpêtrière, 83, Bd de l Hopital, 7 5651 Paris cedex 13, France
    Gastroenterol Clin Biol 32:S82-9. 2008
    ..Effective management strategies that encompass patient and viral factors are necessary to improve the long-term outlook for coinfected patients...
  33. ncbi request reprint Treatment of hepatitis C virus and human immunodeficiency virus coinfection: from large trials to real life
    P Cacoub
    Service de Médecine Interne and CNRS UMR 7087, Hopital de la Pitie, Paris, France
    J Viral Hepat 13:678-82. 2006
    ..The main reasons are a treatment that may be deemed questionable (minimal hepatic lesions, alcohol, active drug use), a lack of available liver biopsy, a psychiatric contraindication and physician conviction of poor patient compliance...
  34. ncbi request reprint Immunotherapy of chronic hepatitis B by anti HBV vaccine: from present to future
    M L Michel
    Unite de Recombinaison et Expression Genetique, INSERM U 163, Institut Pasteur, 75724 Cedex 15, Paris, France
    Vaccine 19:2395-9. 2001
    ....
  35. doi request reprint Expression of defective hepatitis B virus particles derived from singly spliced RNA is related to liver disease
    Patrick Soussan
    Pathogenèse des Hépatites Virales B et Immunothérapie, Institut National de la Santé et de la Recherche Médicale U845, Paris, France
    J Infect Dis 198:218-25. 2008
    ..The present study was designed to quantify the expression of defective HBV (dHBV) and wild-type HBV (wtHBV) genomes in the serum of patients with HBV infection and its relation to the severity of liver disease...
  36. ncbi request reprint Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial
    Fabrice Carrat
    Groupe Hospitalier Universitaire Est, Universite Paris 6, INSERM U444, Paris, France
    JAMA 292:2839-48. 2004
    ..Most data on the virologic efficacy and safety of the combination of peginterferon alfa-2b and ribavirin in coinfected patients come from uncontrolled studies...
  37. ncbi request reprint The impact of haematopoietic growth factors on the management and efficacy of antiviral treatment in patients with hepatitis C virus
    Pascal Lebray
    Unité d Hépatologie, Hopital Necker, Paris, France
    Antivir Ther 10:769-76. 2005
    ..To evaluate the benefits of haematopoietic growth factors (HGFs) during the treatment of chronic hepatitis C virus (HCV) infection with severe haematotoxicity...
  38. ncbi request reprint Histopathologic efficacy of ribavirin monotherapy in kidney allograft recipients with chronic hepatitis C
    Helene Fontaine
    Unité d Hépatologie, Hopital Necker, Paris, France
    Transplantation 78:853-7. 2004
    ..The aim of this study was to analyze the biologic, virologic, and histopathologic efficacy of ribavirin alone in kidney allograft recipients with hepatitis C...
  39. ncbi request reprint Stable recovery from HCV in HIV-HCV co-infection under antiretroviral therapy
    Jean David Zeitoun
    AP HP, Hopital Cochin, Hepatologie, Paris, France
    J Clin Virol 40:71-3. 2007
    ..The respective effect of immune restoration and of high doses of ritonavir are discussed...
  40. ncbi request reprint The tolerance and efficacy of interferon-alpha in haemodialysis patients with HCV infection: a multicentre, prospective study
    F Degos
    , , 100 Boulevard du Gl Leclerc, F-92110 Clichy, France
    Nephrol Dial Transplant 16:1017-23. 2001
    ..Sustained response is fairly high in patients who have 12 months of treatment and seems to be based on the immune status of the patients (ALT) and the cumulative doses of interferon...
  41. ncbi request reprint Reversibility of hepatitis C virus-related cirrhosis
    Stanislas Pol
    Unité d Hépatologie, Hopital Necker, Paris, France
    Hum Pathol 35:107-12. 2004
    ..In conclusion, long-lasting suppression of the necroinflammatory activity of liver disease and/or antifibrogenetic effects of interferon-alpha may allow regression of cirrhosis...
  42. doi request reprint New trends in hepatitis C management
    Vincent Mallet
    Paris Descartes University, Department of Hepatology, APHP, Cochin Hospital, INSERM U 567, F 75014, Paris, France
    Presse Med 39:446-51. 2010
    ..Current epidemiologic models suggest that the incidence of HCC and of the mortality associated with chronic HCV infection will continue to increase through 2015, a finding consisting with the perception of liver specialists today...
  43. doi request reprint Treatment of chronic hepatitis C in sickle cell disease and thalassaemic patients with interferon and ribavirin
    David Ancel
    Hepatology Department, Tenon Hospital, Assistance Publique Hopitaux de Paris, Paris, France
    Eur J Gastroenterol Hepatol 21:726-9. 2009
    ..Ribavirin is usually contraindicated in patients with haemolytic anaemia. This pilot study evaluated the efficacy and safety of antiviral treatment in patients with sickle cell disease (SCD) or beta-thalassaemia major (TM)...
  44. ncbi request reprint Spontaneous hepatic decompensation in patients coinfected with HIV and hepatitis C virus during interferon-ribavirin combination treatment
    Firouzé Bani-Sadr
    INSERM U707, Faculte de Medecine Hopital Saint Antoine, Paris, France
    Clin Infect Dis 41:1806-9. 2005
    ..02), and elevated total bilirubin level (OR, 7.9; 95% CI, 1.08-93.3; P<.03). Didanosine should thus not be given to patients with cirrhosis, particularly when treatments for HCV and HIV infections have to be administered concomitantly...
  45. ncbi request reprint Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients
    Vincent Mallet
    Universite Paris Descartes, France
    AIDS 21:187-92. 2007
    ..To describe and explain the syndrome of HIV-associated cryptogenic liver disease in eight consecutive patients suffering from portal hypertension...
  46. ncbi request reprint FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest
    Anais Vallet-Pichard
    Universite Paris Descartes, Paris, France
    Hepatology 46:32-6. 2007
    ..45 or >3.25 (kappa = 0.561, P < 0.01). A FIB-4 value <1.45 or >3.25 (64.6% of the cases) was concordant with FibroTest results in 92.1% and 76%, respectively...
  47. ncbi request reprint High hepatitis C virus viral load in HIV/hepatitis C virus-co-infected patients: a different influence of protease inhibitor and non-protease inhibitor-based HAART?
    Firouzé Bani-Sadr
    Groupe Hospitalier Universitaire Est, Universite Paris 6, INSERM U707, Paris, France
    AIDS 21:1645-8. 2007
    ..Antiretroviral therapy in general was independently associated with lower HCV viral load. This suggests that HCV viral load kinetics could differ according to the choice of HAART regimen...
  48. ncbi request reprint Efficacy and safety of adefovir dipivoxil in kidney recipients, hemodialysis patients, and patients with renal insufficiency
    Helene Fontaine
    Liver Unit, Necker Hospital, Paris, France
    Transplantation 80:1086-92. 2005
    ..This study analyzes the biochemical, serological, and virological efficacy and the safety of adefovir dipivoxil in patients with renal disturbances...
  49. ncbi request reprint HIV infection and hepatic enzyme abnormalities: intricacies of the pathogenic mechanisms
    Stanislas Pol
    Unité d Hépatologie and INSERM U 370, Hopital Necker, Paris, France
    Clin Infect Dis 38:S65-72. 2004
    ..g., methamphetamine). A better understanding of these complex interactions, including adjustments of dosages of antiretroviral drugs, will probably help in the management of HIV-infected patients with liver enzyme abnormalities...
  50. ncbi request reprint Efficacy and limitations of a specific immunotherapy in chronic hepatitis B
    S Pol
    Unité d Hépatologie, Hĵpital Necker, Paris, France
    J Hepatol 34:917-21. 2001
    ..This controlled study aimed to evaluate the efficacy and potential side effects of hepatitis B virus (HBV) vaccination as active immunotherapy in HBV-related chronic hepatitis...
  51. doi request reprint T-cell responses to hepatitis B splice-generated protein of hepatitis B virus and inflammatory cytokines/chemokines in chronic hepatitis B patients. ANRS study: HB EP 02 HBSP-FIBRO
    F Bayard
    Departement de Virologie, Laboratoire de pathogenèse des virus de l hépatite B, Institut Pasteur, France
    J Viral Hepat 19:872-80. 2012
    ..The pattern of cytokines and chemokines in sera was linked to HBV viral load and was consistent with the level of inflammation during chronic hepatitis...
  52. ncbi request reprint Influence of HFE gene polymorphism on the progression and treatment of chronic hepatitis C
    P Lebray
    Unité d Hépatologie, CHU Necker, Paris, France
    J Viral Hepat 11:175-82. 2004
    ..The H63D mutation might form part of an immunogenetic profile influencing the response to interferon therapy...
  53. ncbi request reprint Microsporidia infection in patients with the human immunodeficiency virus and unexplained cholangitis
    S Pol
    Unit of Hepatology, Hôpital Necker Laënnec, Paris, France
    N Engl J Med 328:95-9. 1993
    ....
  54. doi request reprint [Management of chronic hepatitis C in 2008]
    S Pol
    Service d Hepatologie, Hopital Cochin, 27, rue du Faubourg Saint Jacques, 75014 Paris, France
    Gastroenterol Clin Biol 32:S121-4. 2008
  55. pmc Hepatitis B virus-human immunodeficiency virus co-infection in France: a cross-sectional multicentre study
    D Sene
    hôpital La Pitié Salpêtrière, Service de Medecine Interne, Paris, France
    Epidemiol Infect 135:409-16. 2007
    ..45.7%, P<10(-4)), mainly lamivudine and tenofovir. Significant improvements in the management of such patients are awaited mainly in the appraisal of liver disease by either liver biopsy or non-invasive alternatives to liver biopsy...
  56. doi request reprint Acquired protein S deficiency leads to obliterative portal venopathy and to compensatory nodular regenerative hyperplasia in HIV-infected patients
    Vincent O Mallet
    Institut Cochin, Universite Paris Descartes, CNRS, UMR 8104, INSERM, U567, Paris, France
    AIDS 23:1511-8. 2009
    ..To identify the mechanism of nodular regenerative hyperplasia in HIV-infected patients...
  57. ncbi request reprint Treatment of hepatitis C virus in human immunodeficiency virus infected patients in "real life": modifications in two large surveys between 2004 and 2006
    Patrice Cacoub
    Universite Pierre et Marie Curie Paris 6, CNRS, UMR 7087, Paris, France
    J Hepatol 48:35-42. 2008
    ..To analyze the barriers to HCV treatment in HIV-HCV co-infected patients and their evolution between 2004 and 2006...
  58. doi request reprint Treatment of HBV-related cirrhosis
    Anais Vallet-Pichard
    Universite Paris Descartes, APHP, INSERM U 567, Hopital Cochin, Unité d Hépatologie, 27 rue du Faubourg Saint Jacques, Paris Cedex 14, France
    Expert Rev Anti Infect Ther 7:527-35. 2009
    ..Patients with cirrhosis require careful monitoring to detect resistance and prevent flares, and also to screen for hepatocellular carcinoma, portal hypertension and liver failure...
  59. ncbi request reprint Intrahepatic hepatitis C virus RNA quantification in microdissected hepatocytes
    Giovanna Vona
    INSERM U370 Pasteur, Necker Faculty, Paris, France
    J Hepatol 40:682-8. 2004
    ..We have therefore investigated the feasibility of quantifying HCV replication using a laser-based microdissection technique...
  60. ncbi request reprint [A puzzling case of portal hypertension in a patient with human immunodeficiency and hepatitis C virus co-infection]
    Vincent Mallet
    INSERM U567, Unité d Hépatologie, Pôle d hépato gastroentérologie médicochirurgical, Hopital Cochin, 27 rue du Faubourg Saint Jacques, Paris
    Gastroenterol Clin Biol 31:878-80. 2007
    ..Vascular liver diseases seem to be a new cause of chronic liver disease in HIV-infected patients receiving combined antiretroviral therapy. The syndrome of HIV-associated liver vasculopathy is discussed...
  61. ncbi request reprint Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C
    Vincent Mallet
    Université Paris Descartes Assistance Publique Hôpitaux de Paris, Hopital Cochin, INSERM U 567, Paris, France
    Ann Intern Med 149:399-403. 2008
    ..The effect of regression of cirrhosis in chronic hepatitis C is unknown...
  62. doi request reprint Comparison of non-invasive liver fibrosis biomarkers in HIV/HCV co-infected patients: the fibrovic study--ANRS HC02
    Patrice Cacoub
    Universite Pierre et Marie Curie Paris 6, CNRS, UMR 7087, Paris, France
    J Hepatol 48:765-73. 2008
    ..To compare non-invasive biological liver fibrosis scores, as alternatives to liver biopsy, in HIV/HCV co-infected patients...
  63. pmc Pathological evolution of hepatitis C virus-"Healthy carriers"
    Rodolphe Sobesky
    INSERM U785, Centre Hepato Biliaire, Hopital Paul Brousse, Villejuif, France
    World J Gastroenterol 14:3861-5. 2008
    ..To determine factors associated with fibrosis progression in hepatitis C virus (HCV)-infected patients without significant initial pathological lesions...
  64. ncbi request reprint Hepatitis C virus in the semen of men coinfected with HIV-1: prevalence and origin
    Aurélie Briat
    Virology Laboratory, Universite Rene Descartes, Paris, France
    AIDS 19:1827-35. 2005
    ..To compare the prevalence of hepatitis C (HCV) RNA in semen from men infected with HCV and those coinfected with HIV-1/HCV and to study the origin of HCV shed in semen...
  65. doi request reprint Insulin resistance impairs sustained virological response rate to pegylated interferon plus ribavirin in HIV-hepatitis C virus-coinfected patients: HOMAVIC-ANRS HC02 Study
    Patrice Cacoub
    Universite Pierre et Marie Curie Paris 6, CNRS, UMR 7087, Paris, France
    Antivir Ther 14:839-45. 2009
    ..The aim of this study was to assess the effect of insulin resistance (IR) on the response to hepatitis C virus (HCV) therapy in HIV-HCV-coinfected patients...
  66. doi request reprint Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial
    Odile Launay
    Paris Descartes University, France
    JAMA 305:1432-40. 2011
    ..Alternative schedules more immunogenic than the standard hepatitis B vaccine regimen are needed in patients with human immunodeficiency virus 1 (HIV-1) infection...
  67. ncbi request reprint Direct and indirect evidence for the reversibility of cirrhosis
    Jeanne Serpaggi
    Service d Hépatologie et INSERM U 567, Hopital Necker Enfants Malades, Paris, France
    Hum Pathol 37:1519-26. 2006
    ..Using repeated liver biopsies, clinicobiochemical, radiologic, and endoscopic tests, we provide evidence for potential reversibility of cirrhosis after long-lasting suppression of the necro-inflammatory activity of liver disease...
  68. doi request reprint Brief communication: case reports of ribavirin treatment for chronic hepatitis E
    Vincent Mallet
    Institut Cochin, Université Paris Descartes Unité Mixte de Recherche S1016, Paris, France
    Ann Intern Med 153:85-9. 2010
    ..There is currently no accepted treatment of chronic hepatitis E virus (HEV) infection...
  69. doi request reprint Care of hepatitis C virus infection in human immunodeficiency virus-infected patients: modifications in three consecutive large surveys between 2004 and 2009
    Patrice Cacoub
    Universite Pierre et Marie Curie PARIS6, CNRS, UMR 7211, France
    J Hepatol 53:230-7. 2010
    ..To analyze the care of HCV infection in HIV-HCV coinfected patients and its progression between 2004 and 2009...
  70. ncbi request reprint Reversibility of cirrhosis in HIV/HBV coinfection
    Vincent O Mallet
    Universite Paris Descartes, Paris, France
    Antivir Ther 12:279-83. 2007
    ..In conclusion, a HAART regimen including tenofovir disoproxil fumarate in a HBV/HIV-coinfected cirrhotic patient might lead to sustained HBV viral suppression and result in cirrhosis reversal...
  71. pmc Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib
    Romain Coriat
    Center for Research on Angiogenesis Inhibitors CERIA, Hopital Cochin, AP HP, Paris, France
    PLoS ONE 6:e16978. 2011
    ..No portal venous flow modification was observed in the control group. Sorafenib is the first anti-angiogenic therapy to demonstrate a beneficial and reversible decrease of portal venous flow among cirrhotic patients...
  72. doi request reprint [Management of the risk of hepatitis B virus reactivation in patients receiving immunosuppressive and immunomodulatory agents in internal medicine: data from the REACTI-B survey and proposal for a management algorithm]
    B Terrier
    Service de Medecine Interne, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Rev Med Interne 33:4-12. 2012
    ....
  73. ncbi request reprint Hepatitis C and human immune deficiency coinfection at the era of highly active antiretroviral therapy
    S Pol
    Unité d hépatologie et Inserm U 370, Hopital Necker, Paris, France
    J Viral Hepat 9:1-8. 2002
    ....
  74. doi request reprint Automation of the Hepascore and validation as a biochemical index of liver fibrosis in patients with chronic hepatitis C from the ANRS HC EP 23 Fibrostar cohort
    Jérôme Guéchot
    Laboratoire de Biochimie A, Hopital Saint Antoine, AP HP, Paris, France
    Clin Chim Acta 411:86-91. 2010
    ....
  75. ncbi request reprint Human leukocyte antigen class II alleles may contribute to the severity of hepatitis C virus-related liver disease
    Sophie Hue
    Laboratory of Immunology, Hopital Necker, Paris, France
    J Infect Dis 186:106-9. 2002
    ..HLA class II alleles may weakly contribute to the severity of HCV liver disease. Of persons infected with HCV, only 15%-20% spontaneously clear the virus, and the rest become chronically infected...
  76. doi request reprint Interferon gamma receptor 2 gene variants are associated with liver fibrosis in patients with chronic hepatitis C infection
    Bertrand Nalpas
    Unité d Hépatologie, Institut National de la Sante et de la Recherche Medicale, U567, Hopital Cochin, Paris, France
    Gut 59:1120-6. 2010
    ..Only a minority of patients with chronic hepatitis C virus (HCV) infection develops severe liver fibrosis, a process that may be controlled by human genetic factors...
  77. ncbi request reprint Prevalence of mixed cryoglobulins in relation to CD4 cell count among patients coinfected with HIV and hepatitis C virus
    Laurent Aaron
    Service des Maladies Infectieuses et Tropicales, Assistance Publique Hopitaux de Paris, Centre Hospitalier Universitaire Necker Enfants Malades, Paris, France
    Clin Infect Dis 40:306-8. 2005
    ..3%) of 19 patients with a CD4 cell count of <200 cells/ micro L (P=.0064). Cell-mediated immunity could, therefore, contribute to the production of HCV-associated cryoglobulins...
  78. ncbi request reprint Optimizing treatment outcomes in chronic hepatitis C: management of non-response
    Stanislas Pol
    Unité d Hépatologie, Inserm U 567 Hôpital Cochin, Paris, France
    Antivir Ther 11:955-70. 2006
    ..This review explores putative management strategies for patients who have previously failed to achieve a response to IFN-based therapy, and summarises retreatment options that have been, and are currently being evaluated...
  79. ncbi request reprint Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d'Etude des Lymphomes de l'Adulte programs
    Caroline Besson
    Service d hématologie adulte, Hopital Necker Enfants Malades, APHP, Paris, France
    J Clin Oncol 24:953-60. 2006
    ..Epidemiologic studies show an association between hepatitis C virus (HCV) and B-cell non-Hodgkin's lymphoma (NHL). Treatment and outcome of patients with diffuse large-cell lymphoma (DLCL) and HCV infection are still a matter of debate...
  80. doi request reprint [Alcoholic hepatitis]
    J B Trabut
    Unité d Hépatologie, Inserm U1016, Universite Paris Descartes, Hopital Cochin Saint Vincent de Paul, AP HP, 27, rue du Faubourg Saint Jacques, 75014 Paris, France
    Rev Med Interne 33:311-7. 2012
    ..Liver transplantation can be proposed to highly selected patients who do not respond to medical therapy. In any case, long-term prognosis will primarily depend on the maintenance of alcohol abstinence...
  81. pmc Discrimination of agonist and antagonist forms of CXCL10 in biological samples
    A Casrouge
    Laboratory of Dendritic Cell Biology, Department of Immunology, Institut Pasteur, Paris, France
    Clin Exp Immunol 167:137-48. 2012
    ....
  82. ncbi request reprint Severe evolution of chronic hepatitis C in renal transplantation: a case control study
    Hervé Zylberberg
    Service d Hépatologie et INSERM U 370, Hopital Saint Louis, Paris, France
    Nephrol Dial Transplant 17:129-33. 2002
    ..To evaluate the impact of kidney transplantation on histopathological progression of hepatitis C virus (HCV)-related liver disease...
  83. ncbi request reprint Intrahepatic virus-specific IL-10-producing CD8 T cells prevent liver damage during chronic hepatitis C virus infection
    Michal Abel
    INSERM, U561 Equipe AVENIR, Paris, France
    Hepatology 44:1607-16. 2006
    ..Therapeutic modulation of the intrahepatic balance between specific and bystander CD8 T cells might be beneficial in patients with chronic hepatitis C...
  84. pmc Changes to the natural killer cell repertoire after therapeutic hepatitis B DNA vaccination
    Daniel Scott-Algara
    Unité de Régulation des Infections Rétrovirales, Institut Pasteur, Paris, France
    PLoS ONE 5:e8761. 2010
    ..We previously reported the induction or reactivation of T cell responses in chronic hepatitis B patients vaccinated with a DNA encoding hepatitis B envelope proteins during a phase I clinical trial...
  85. ncbi request reprint [Co-infection HIV/HBV]
    Stanislas Pol
    Service d Hepatologie, Hopital Necker, 149, rue de Sevres, 75743 Paris Cedex 15, France
    Gastroenterol Clin Biol 26:518-21. 2002
  86. pmc Serum alpha-fetoprotein predicts treatment outcome in chronic hepatitis C patients regardless of HCV genotype
    Hendy Abdoul
    Unité d Epidémiologie des Maladies Emergentes, Institut Pasteur, Paris, France
    PLoS ONE 3:e2391. 2008
    ..7 ng/ml) (58.7% and 19.2%, respectively; P<0.0001). Serum AFP should be added to the list of factors predictive of treatment response in chronic hepatitis C...
  87. ncbi request reprint Impact of hepatitis B virus basic core promoter mutations on T cell response to an immunodominant HBx-derived epitope
    Silvina Laura Malmassari
    INSERM U812, Pathogenèse des Hépatites Virales B et Immunothérapie, Paris, France
    Hepatology 45:1199-209. 2007
    ..We further demonstrated that these viral mutant sequences activated T cells specific for the immunodominant epitope only weakly, if at all. This is the first study linking BCP mutations and HBx-specific T cell responses...
  88. doi request reprint Sexually transmitted hepatitis C virus superinfection in HIV/hepatitis C virus co-infected men who have sex with men
    Jade Ghosn
    AP HP, EA MRT 3620, Universite Paris Descartes, Department of Virology, Necker Hospital, Paris, France
    AIDS 22:658-61. 2008
    ..HCV serology and serum HCV RNA should be examined periodically in HIV-infected men who have sex with men engaging in high-risk sexual behaviours...
  89. ncbi request reprint HCV infection and hemodialysis
    Stanislas Pol
    Unité d Hépatologie et Inserm V 370, Hopital Necker, Paris, France
    Semin Nephrol 22:331-9. 2002
    ..Indeed, alpha-interferon is contraindicated in kidney recipients given the risk for rejection. Preventive treatment for HCV is only respect for universal hygiene rules in the dialysis setting because there is no available vaccine...
  90. ncbi request reprint [The role of contrast-enhanced ultrasonography for the detection of hepatocellular carcinoma]
    J M Correas
    Service de Radiologie Adulte, Hopital Necker, Paris, France
    J Radiol 85:690-703. 2004
    ..However, US in cirrhosis remains a difficult examination, with limitations due to limited access to sub-diaphragmatic localization, attenuation of the ultrasound beam and shortness of the arterial phase...
  91. ncbi request reprint Therapeutic vaccination in chronic hepatitis B virus carriers
    Stanislas Pol
    Unité d Hépatologie, Liver Unit, Hopital Cochin, Université Paris V René Descartes and Inserm U 567, 27 Rue du Faubourg Saitn Antoine, 75014 Paris, France
    Expert Rev Vaccines 5:707-16. 2006
    ....
  92. ncbi request reprint Immunomodulatory drugs and therapeutic vaccine in chronic hepatitis B infection
    Pascal Lebray
    Service d Hepatologie, Hopital Necker Enfants Malades, 75730 Paris Cedex 15, France
    J Hepatol 39:S151-9. 2003
  93. ncbi request reprint [Treatment of delta (type D) hepatitis]
    Stanislas Pol
    Unité d hépatologie et Inserm U 370, Hopital Necker, Paris, France
    Gastroenterol Clin Biol 29:384-7. 2005
  94. pmc Dual role of CCR2 in the constitution and the resolution of liver fibrosis in mice
    Claudia Mitchell
    Institut Cochin, Universite Paris Descartes, Centre National de Researche Scientifique UMR 8104, Paris, France
    Am J Pathol 174:1766-75. 2009
    ..In conclusion, these findings underline the role of the CCR2 signaling pathway in both the constitution and resolution of liver fibrotic scars...
  95. doi request reprint Why actively promote vaccination in patients with cirrhosis?
    Pierre Loulergue
    Universite Paris Descartes, Faculte de Medecine, Paris, France
    J Clin Virol 46:206-9. 2009
    ..Few data regarding vaccination coverage are available, but studies suggest that immunization rates are too low in this population...
  96. doi request reprint Plasmacytoid dendritic cells move down on the list of suspects: in search of the immune pathogenesis of chronic hepatitis C
    Matthew L Albert
    The Laboratory of Dendritic Cell Biology, Department of Immunology, Institut Pasteur, Paris, France
    J Hepatol 49:1069-78. 2008
    ..Thus, instead of being the culprit, pDCs may in fact represent a novel therapeutic target in order to improve upon existing therapies for treating HCV patients...
  97. ncbi request reprint Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers
    Maryline Mancini-Bourgine
    Carcinogénèse Hépatique et Virologie Moléculaire Institut National de la Santé et de la Recherche Médicale Unité 370, Institut Pasteur, Paris, France
    Hepatology 40:874-82. 2004
    ..We demonstrate that DNA vaccination can specifically but transiently activate T-cell responses in some chronic HBV carriers who do not respond to current antiviral therapies...
  98. doi request reprint Influence of liver biopsy on abstinence in alcohol-dependent patients
    Jean Baptiste Trabut
    Unité d Hépatologie Hôpital Cochin, 27, rue du Faubourg St Jacques, 75014 Paris, France
    Alcohol Alcohol 43:559-63. 2008
    ..Liver biopsy indication for the evaluation of alcoholic liver disease is controversial. Our aim was to investigate the influence of the biopsy on the patients' motivation for abstinence...
  99. ncbi request reprint Veno-occlusive disease of the liver in renal transplant patients
    Anais Vallet-Pichard
    Unité d hépatologie et Inserm U 370, Service de transplantation rénale, Service d Anatomopathologie, Hopital Necker, Paris, France
    Nephrol Dial Transplant 18:1663-6. 2003
  100. ncbi request reprint Early virologic failure in HIV-coinfected hepatitis C patients treated with the peginterferon-ribavirin combination: does abacavir play a role?
    Firouzé Bani-Sadr
    J Acquir Immune Defic Syndr 45:123-5. 2007
  101. ncbi request reprint [Natural history of hepatitis B infection]
    Stanislas Pol
    Unité d hépatologie et Inserm U 370, Hopital Necker, Paris
    Presse Med 35:308-16. 2006
    ..Chronic HBV infection is a major public health problem, particularly in developing countries, and it requires that efforts to make HBV vaccination universal be intensified...